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Background: Even after quitting illicit drugs, tobacco abuse remains a major cause of morbidity and mortality in
former injection drug users. An important unmet need in this population is to have effective interventions that can
be used in the context of community based care. Contingency management, where a patient receives a monetary
incentive for healthy behavior choices, and incorporation of individual counseling regarding spirometric “lung age”
(the age of an average healthy individual with similar spirometry) have been shown to improve cessation rates in
some populations. The efficacy of these interventions on improving smoking cessation rates has not been studied
among current and former injection drug users.
Methods: In a randomized, factorial design study, we recruited 100 active smokers from an ongoing cohort study
of current and former injection drug users to assess the impact of contingency management and spirometric lung
age on smoking cessation. The primary outcome was 6-month biologically-confirmed smoking cessation comparing
contingency management, spirometric lung age or both to usual care. Secondary outcomes included differences in
self-reported and biologically-confirmed cessation at interim visits, number of visits attended and quit attempts,
smoking rates at interim visits, and changes in Fagerstrom score and self-efficacy.
Results: Six-month biologically-confirmed smoking cessations rates were 4% usual care, 0% lung age, 14% contingency
management and 0% for combined lung age and contingency management (p = 0.13). There were no differences in
secondary endpoints comparing the four interventions or when pooling the lung age groups. Comparing contingency
management to non-contingency management, 6-month cessation rates were not different (7% vs. 2%; p = 0.36), but
total number of visits with exhaled carbon monoxide-confirmed abstinence were higher for contingency management
than non-contingency management participants (0.38 vs. 0.06; p = 0.03), and more contingency management
participants showed reduction in their Fagerstrom score from baseline to follow-up (39% vs. 18%; p = 0.03).
Conclusions: While lung age appeared ineffective, contingency management was associated with more short-term
abstinence and lowered nicotine addiction. Contingency management may be a useful tool in development of
effective tobacco cessation strategies among current and former injection drug users.
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Injection drug users (IDUs) have among the highest
prevalence of tobacco dependence, yet represent an
understudied population in terms of smoking cessation
strategies [1-4]. IDUs report smoking prevalence four
times that of the general US population [5]. Low socio-
economic status, low educational achievement and poly-
substance abuse are prevalent among IDUs and each is
independently associated with increased tobacco de-
pendence [6-8]. At the individual level, factors in each of
the five psychosocial domains (personality, drug use be-
havior, family, peer and environment) have been shown
to be independently associated with nicotine dependence
in an urban cohort [9,10].
Studies have consistently demonstrated that the major-
ity of illicit drug users are interested in quitting smoking
[3,11]. As many as 61% of IDUs in substance abuse
treatment programs report a desire to quit tobacco use,
with an average of five prior quit attempts per person
[12,13]. Designing effective and feasible smoking cessa-
tion programs tailored for this population may substan-
tially improve cessation. Contingency management is an
approach which provides a structured incentive contin-
gent upon changes in a participant’s behavior [14,15].
Typically, these incentives are in the form of a voucher
or monetary reward for achieving a pre-specified thera-
peutic target. Initially employed as a motivation for illicit
drug use cessation [16-19], several studies have demon-
strated moderate efficacy in improving tobacco cessation
rates [20-24]. A second novel approach to smoking ces-
sation uses the concept of “lung age” as a motivational
tool for smoking cessation [25]. Spirometric measure-
ments of lung function are typically reported in absolute
terms or percentage of predicted values based upon a
referent population. Lung age reports spirometry results
using the age of an average healthy individual with simi-
lar spirometry results (i.e., “You are 50 years old, but
you have the lungs of a 70 year old”). The use of lung
age as a motivational tool has been shown to improve
biologically-confirmed smoking cessation endpoints in
community-based clinic populations [25] and perceived
smoking-related risks, worries and desire to quit in col-
lege smokers [26]. To date, no study has evaluated the
efficacy of the positive reinforcement associated with
contingency management and negative reinforcement of
lung age-based counseling for improving smoking cessa-
tion among IDUs.
The AIDS Linked to the Intravenous Experience
(ALIVE) study, a prospective, longitudinal cohort of
persons with a history of injecting drugs followed in
Baltimore, Maryland since 1988, represents an ideal popu-
lation to explore novel smoking cessation interventions
[27]. This cohort has nearly ubiquitous cigarette smoking
[28,29] and recently instituted serial spirometric measuresinto the existing data collection protocol. In this study, we
assess the impact of contingency management and spiro-
metric lung age as motivational tools to improve 6-month
biologically confirmed smoking cessation rates in a cohort
of 100 current smokers in a randomized, factorial design
study. We hypothesized that the individuals who receive
smoking cessation counseling including contingency man-
agement or spirometric lung age or both would be more
likely to achieve tobacco cessation and have greater
change in self-efficacy and intention to quit at 6 months
compared to usual care.
Methods
Participant recruitment and eligibility
As described previously [27,30], ALIVE has recruited
residents of Baltimore, MD since 1988 who were
≥18 years of age and had a history of injecting drugs. Bi-
annual study visits include standardized questionnaires,
a clinical examination, and biospecimen collection. Since
2007, pre-bronchodilator spirometry testing has been
performed at each study visit. From March 16, 2011 to
February 3, 2012, ALIVE participants presenting for a
scheduled lung sub-study visit were screened for inclu-
sion in this trial. Eligibility requirements included
current cigarette smoking (defined as a history of smok-
ing at least 100 cigarettes in their lifetime as well as
reporting any cigarette smoking in the last month), no
current involvement in a smoking cessation program, no
current use of nicotine replacement therapy or other
smoking cessation pharmacological treatments (bupro-
pion, varenicline), interested in involvement in a smok-
ing cessation trial and the ability to perform spirometry.
After screening, the study was described to participants,
and if interested, written informed consent was obtained.
The study was approved by the IRB of Johns Hopkins
University.
Randomization and study design
Prior to study initiation, 120 sequentially numbered
opaque sealed envelopes were externally prepared that in-
cluded random assignment to one of four interventions.
Randomization sequence was computer-generated using a
block randomization approach with randomly ordered
four and eight sample blocks. After informed consent was
obtained and baseline data including smoking-related
questionnaires, assessment of self-efficacy and intention to
quit smoking, exhaled carbon monoxide (eCO) level and
spirometry were completed, study staff was provided the
next sequential envelope which assigned the intervention.
Study visit protocol
The overall design of the study included one baseline
visit and six follow-up visits over six months. All visits
occurred at the ALIVE research clinic site. Assessment
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ometry measurement occurred at the baseline visit.
Follow-up visits occurred at one, two and four weeks,
then two, three and six months from baseline visit. An
increased frequency of visits early in the study was in-
cluded to enhance protocol compliance.
Study procedures
At baseline and follow-up visits, all participants com-
pleted smoking-related questionnaires, assessment of
self-efficacy and intention to quit smoking and eCO
measurement. At all visits, participants also received a
brief standardized counseling session on the harms of
smoking and were offered information on smoking ces-
sation resources available in the community. If the par-
ticipant inquired about nicotine replacement therapy, he
or she was advised to contact their primary care pro-
vider to discuss potential therapeutic options. Blood was
obtained for serum cotinine analysis at six month visits.
Usual care
At baseline and follow-up visits, the usual care group
reviewed baseline spirometry results of their lung func-
tion reported as a percentage of predicted values, com-
municated in a standardized written format. Lung
function was first described as the numerical percent
predicted value, and defined as normal if the forced ex-
piratory volume in one second (FEV1) was equal or
greater to 80% of predicted value. If normal, the report
stated “Even though your lung function is normal, it is
still important to quit smoking to prevent future damage
to the lungs.” If the results were abnormal, the report
stated “This suggests that your lungs may already be
damaged by smoking. Quitting smoking now can slow
the rate of damage of the lungs.”
Contingency management
Individuals randomized to contingency management re-
ceived similar interventions as the usual care group.
Additionally, it was explained to participants that they
would receive monetary compensation for biological
confirmation of tobacco cessation. At each visit, exhaled
carbon monoxide levels were checked, and if eCO was
<7 ppm, participants received compensation in a manner
modified from the methodology of Shoptaw [31]. The
first negative eCO resulted in $25 payment, with subse-
quent negative eCO visits increasing $5 in payment to a
maximum of $50. If the participant had an eCO consist-
ent with recent tobacco use, they received no payment
and the payment structure reset to the starting amount.
Lung age intervention
For individuals randomized to lung age intervention, spi-
rometric results were reviewed in the context of lungage [25]. Visual graphs were used to explain how the
lung function normally reduces with age and that smok-
ing can damage lung in a manner similar to more rapid
aging. The written report included their chronological
age and lung age. A similar description of normal or ab-
normal results was provided as in the usual care inter-
vention, although the threshold to define abnormal was
lung age exceeding chronological age.Combined contingency management and lung age
Individuals randomized to this intervention received a
combination of the lung age and contingency manage-
ment protocols described above.Study measures
Pre-bronchodilator spirometry FEV1 and forced vital
capacity (FVC) was measured using KOKO® pneumo-
tachometers (nSpire Health Inc, Longmont, CO) in ac-
cordance with American Thoracic Society guidelines
[32]. Percent predicted values and lung age were calcu-
lated using standard formulas [33]. eCO measurements
were performed with portable CO monitor (Breath CO,
Clement Clarke Intl., Essex UK) with active smoking de-
fined as an exhaled CO >7 ppm [34]. Self-efficacy and
intention to quit smoking was assessed using a modified
version of the Prochaska stages of change questionnaire
[35]. Nicotine addiction was assessed with the Fagerstrom
score [36]. Serum cotinine was measured via radio-
immunoassay ELISA (Calbiotech, Spring Valley CA), with
a threshold of ≥6 ng/mL indicative of active smoking [37].Outcome measure and statistical analysis
The primary outcome of this study was the difference be-
tween interventions in six-month biologically-confirmed
smoking cessation, defined as self-report of non-smoking
in the last seven days combined with negative eCO and
serum cotinine at final study visit. Secondary outcomes in-
cluded differences by intervention in number of visits
attended, smoking rates at interim visits (self-report and
eCO), number of quit attempts, change in Fagerstrom
score, and alterations in self-efficacy. All analyses were
based on intention-to-treat. Comparison of outcomes
across intervention was performed using chi2 test with
Fisher’s exact p-value for small samples of categorical out-
comes and t-test or kruskal-wallis for continuous values as
appropriate. A p-value of <0.05 was used to define statis-
tical significance. It was determined a priori that if no
interaction between lung age and contingency manage-
ment was observed, individual interventions would be
pooled for analysis (i.e., usual care and lung age versus
contingency management and contingency management
with lung age).
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Baseline characteristics
A total of 265 ALIVE participants were screened to
identify 100 eligible and interested participants for this
study (Figure 1). After randomization, 26 participants
were enrolled in each of the usual care and contingency
management interventions while 24 were enrolled in
each of the lung age and lung age combined with con-
tingency management interventions. The median age of
the study cohort was 50 (IQR, 45–56) with 47% female
participants. The median pack-years smoked was 19
(IQR, 12.5-31), with a median Fagerstrom score of 4
(IQR, 2–5). While all participants had a history of IDU,
only 21% reported active injection in the last six months.
However, there remained substantial involvement with
consumption of other illicit drugs and alcohol, with 32%
reporting use of non-intravenous drugs and 51% report-
ing alcohol use in the last six months. For participants
in lung age interventions, the lung age was on average
12 years older than chronological age (median 12; IQR
−1 to 23 years older), with 54% of lung age participants
having a lung age at least ten years older than chrono-
logical age. Randomization resulted in similar baseline
characteristics of the four intervention groups (Table 1).
There was a higher proportion of non-African Americans
in the lung age group when compared to the other
interventions.
Outcomes across all interventions
The six month biologically-confirmed smoking cessa-
tions rate was 4% for usual care, 0% for lung age, 14%265 ALIVE Partic
100 Participa





Completed six month 
follow up 
25 (96%) 
Completed six month 
follow up 
Figure 1 Study screening, randomization and follow-up.for contingency management and 0% for combined lung
age and contingency management. While higher cessa-
tion rates were observed in the contingency management
intervention, this did not achieve statistical significance
(p = 0.13). Using less stringent criteria for smoking ces-
sation (self-report alone or self-report combined with
negative eCO) also did not yield differential six month
cessation rates across all four interventions. There were
no substantial differences in the secondary endpoints of
change in smoking rates (self-report and eCO) at in-
terim visits, change in Fagerstrom score, total number
of visits attended, alterations in self-efficacy and number
of quit attempts comparing the four interventions.
Outcomes comparing contingency management to
non-contingency management
Because there was neither an effect of lung age on
outcomes nor an interaction between contingency man-
agement and lung age, we compared outcomes of the con-
tingency management interventions to non-contingency
management interventions (usual care combined with
lung age alone) (Table 2, Figures 2 and 3). Comparing
contingency management interventions (with and without
lung age) to non-contingency management interventions
(usual care and lung age alone), at six months more indi-
viduals self-reported smoking cessation in the prior seven
days (18% vs. 4%; p = 0.05). There was no statistically sig-
nificant difference in biologically-confirmed six month
smoking cessation rates between contingency manage-
ment and non-contingency management interventions
(7% vs. 2%; p = 0.36). Contingency management was notipants Screened 
nts Consented 
104 Ineligible 
   ·39 not current smokers 
   ·60 lacking spirometry 
   ·3 enrolled in tobacco cessation   
protocol
   ·2 currently using NRT 
61 Not interested in participation 






Completed six month 
follow up 
23 (88%) 
Completed six month 
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Table 1 Baseline characteristics at randomization
Usual care Lung age Contingency
management
Lung age + contingency
management
p-value
N 26 24 26 24
Age, years 52.3 (7.2) 46.1 (8.9) 51.2 (7.5) 49.2 (8.7) 0.09
Female, n (%) 11 (42) 10 (42) 17 (65) 9 (38) 0.18
African American race, n (%) 24 (92) 18 (75) 26 (100) 21 (88) 0.03
Current IDU, n (%) 3 (12) 8 (33) 6 (23) 4 (17) 0.27
Current non-IDU, n (%) 7 (27) 8 (33) 7 (27) 10 (42) 0.64
Current alcohol use, n (%) 15 (58) 12 (50) 12 (46) 12 (50) 0.87
More than 1 drink a day per week, n (%) 15 (58) 12 (50) 12 (46) 12 (50) 0.37
Alcohol or drug treatment in last 6 months, n (%) 9 (35) 10 (42) 4 (15) 9 (38) 0.19
HIV infected, n (%) 6 (23) 4 (17) 4 (15) 6 (25) 0.83
Age first smoked 16.2 (5.0) 16.1 (5.4) 17.1 (5.8) 14.9 (4.4) 0.79
Pack-years, med (IQR) 19.1 (13.7-32) 18.4 (14.1-22.8) 17.8 (11.5-31.0) 20.3 (11.0-35.5) 0.74
Smoking >1 pack per day, n (%) 5 (19) 4 (17) 3 (12) 5 (21) 0.68
Smokers in home, n (%) 18 (69) 20 (83) 15 (58) 19 (79) 0.18
Fagerstrom score, med (IQR) 4 (2–5) 3.5 (2–4) 3.5 (2–5) 4 (3–5.5) 0.54
Pulmonary diagnoses
Asthma, n (%) 6 (23) 5 (21) 8 (31) 5 (22) 0.84
COPD, n (%) 3 (12) 4 (17) 2 (8) 2 (9) 0.79
Both, n (%) 7 (27) 7 (29) 9 (35) 5 (22) 0.79
FEV1
Absolute (L) 2.58 (0.88) 2.58 (0.78) 2.42 (0.62) 2.72 (0.94) 0.74
% predicted 87.2 (20) 84.1 (19) 86.5 (14) 93.7 (21) 0.42
FVC, (L)
Absolute (L) 3.58 (1.27) 3.45 (0.96) 3.18 (0.73) 3.62 (1.13) 0.57
% predicted 96.2 (17) 90.8 (14) 91.4 (12) 99.5 (16) 0.14
FEV1/FVC ratio 0.72 (0.11) 0.74 (0.10) 0.76 (0.06) 0.75 (0.09) 0.62
Lung age – 60.7 (16) – 54.2 (19.8) 0.31
Difference btw lung age and actual age, median (IQR) – 12.5 (5.5 to 28.5) – 11.0 (−10 to 18.5) 0.12
Table 2 Impact of contingency management on smoking habits and nicotine addiction
Non-contingency management Contingency management p-value
6 month cotinine confirmed cessation, n (%) 1 (2) 3 (7) 0.36
6 month eCO confirmed cessation, n (%) 2 (4) 5 (11) 0.27
6 month self-reported cessation, n (%) 2 (4) 8 (18) 0.05
Use of nicotine replacement at 6 month visit, n (%) 2 (4) 7 (16) 0.16
Decreased Fagerstrom from 1st visit, n (%) 8 (18) 17 (39) 0.03
Total number of visitsa, mean (SD) 5.34 (1.83) 5.14 (1.84) 0.59
No. of visits reporting wanting to quit smokinga, mean (SD) 5.12 (1.85) 5.02 (1.83) 0.79
No. of visits reporting trying to quit smokinga, mean (SD) 1.94 (1.92) 2.42 (2.20) 0.25
No. of visits reporting cessationa, mean (SD) 0.10 (0.30) 0.58 (1.28) 0.01
No. of visits with eCO-confirmed cessationa, mean (SD) 0.06 (0.24) 0.38 (0.99) 0.03
aNumber of visits is out of 6 possible.
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Figure 2 Relative effect of contingency management on six-month study outcomes. The figure displays the difference in the percent of
participants reporting 6-month outcomes comparing contingency management to non-contingency management interventions. Center points
represent the estimated difference in proportions with bars showing 95% confidence intervals. Vertical line represents no difference in proportion
between interventions.
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(5.14 vs. 5.34 visits; p = 0.59) nor with more visits express-
ing desire to quit smoking (5.02 vs. 5.12 visits; p = 0.72).
However, participants randomized to contingency man-
agement interventions had more visits reporting not
smoking in the prior seven days confirmed with negative
eCO (0.38 vs. 0.06 visits; p = 0.03) and more visits report-
ing not smoking in the prior seven days (0.58 vs. 0.10
visits; p = 0.01). As well, more participants in the contin-
gency management interventions had a decrease in Fager-
strom score from baseline to six month visit (39% vs. 18%;
p = 0.03). The range in decrease of Fagerstrom score was
−1 to −2 points for both interventions. There was no dif-
ference in measures of self-efficacy between contingency
management and non-contingency interventions. OverFigure 3 Relative effect of contingency management on cumulative s
number of cumulative study visits for the stated outcome, comparing cont
Center points represent the estimated mean difference in study visits with
difference in number of visits between interventions.the study period, in the contingency management inter-
ventions a total of 25 participants were reimbursed for an
initial negative eCO, 11 for a second negative eCO, four
for third negative eCO and one individual achieved four
consecutive eCO measurements. The total reimbursement
over the six month study period for the 50 eligible partici-
pants was $1135 (average of $22.70 per participant).
Discussion
In this study, we examined the impact of contingency
management and the use of spirometric lung age as mo-
tivational tools to improve smoking cessation rates
among IDUs. While neither intervention, when com-
pared to usual care, was associated with a statistical
change in six-month biologically-confirmed cessationtudy outcomes. Number of Study Visits. The displays the difference in
ingency management to non-contingency management interventions.
bars showing 95% confidence intervals. Vertical line represents no
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terventions were associated with more short-term ab-
stinence as measured by exhaled CO and with lower
nicotine addiction as assessed by Fagerstrom score. We
did not observe any effect of using spirometric lung age
as tool to change smoking behavior or nicotine addiction
in this population, and in fact observed that spirometric
lung age may have attenuated the effect of contingency
management when these interventions were combined.
Contingency management has been reported to en-
hance smoking cessation rates in opiod-maintained pa-
tients [20-22]. Most of these studies were of short
duration, and carried out in the context of an existing
drug rehabilitation program. Our study extends these
findings by testing this intervention outside of a metha-
done clinic, for a longer duration of follow-up and with
rigorous biological confirmation of smoking status. In
the setting of a multinational company based in the
United States, a longer duration study of more substan-
tial financial incentives ($750 per person over one year)
for smoking cessation in a non-substance abusing em-
ployee population achieved 15% biologically-confirmed
cessation rates at 9-month follow-up compared to 5% in
an information-only comparator group [24]. We ob-
served a lower proportion of cessation at the final visit,
highlighting the challenges of durable cessation in a sub-
stance abusing population. While a statistical difference
in 6-month cessation rates was not observed in this
study, meaningful differences were observed regarding
the beneficial impact of contingency management on
outcomes indicative of smoking cessation initiation, sug-
gesting potential efficacy of this intervention in IDUs.
These results highlight the potential value in integration
of contingency management programs into existing
smoking cessation programs for substance abusers.
Contingency management for drug abuse treatment
has been extensively evaluated, with consistent data
from high-quality studies demonstrating benefit for
abuse of varied substances (opiates, stimulants, alcohol,
marijuana, tobacco) in different settings (inpatient, out-
patient, community-based) [38-44]. Similar to our study,
contingencies in studies of drug-users have generally
been vouchers or cash-equivalents of modest amount,
delivered for providing biological samples which confirm
abstinence. Modest incentives ($10) improve attendance
at weekly clinic visits among drug users [45] while free
methadone vouchers linked 90% of hospitalized drug
users to outpatient treatment by 3 months (8 times bet-
ter than standard referral) [46]. In addition to drug use,
modest incentives have been shown to improve partici-
pation in HIV counseling and testing, returning to re-
ceive HIV test results, and attendance at referral HIV
clinic visits [47-49]. Contingency management interven-
tions have demonstrated reductions in HIV-related riskbehavior [50,51], increased compliance with tuberculosis
screening [52] and improvements in ART adherence
[53-56]. In our population, we have previously observed
no difference in smoking behaviors or tobacco-cessation
rates by HIV status [28]. Our findings demonstrate that
this intervention may be beneficial in changing early
smoking habits in a challenging population of current
and former drug users, and justify a larger study to ex-
plore this intervention further.
While contingency management did impact some out-
comes of this study, we did not observe any differential
changes in smoking behaviors or perceptions associated
with the use of spirometric lung age as a motivational
tool. This differs from several prior reports in varied
study populations. Parkes and colleagues conducted a
randomized controlled trial of smoking cessation incorp-
orating lung age-based counseling in 561 smokers from
United Kingdom outpatient practices [57]. At 12 month
follow-up, verified quit rates (self-report, carbon monox-
ide and salivary cotinine) were 6.4% in the control group
and 13.6% in the intervention arm (p = 0.005). Average
consumption of cigarettes was also lower in the inter-
vention group. The authors conclude that the use of in-
dividualized lung age feedback is effective at improving
smoking cessation. Lipkus and Prokhorov examined the
effect of providing lung age on college smokers’ per-
ceived smoking-related risks, worries and desire to quit
[26]. Smokers with a lung age that exceeded their
chronological age tended to have greater perceptions of
absolute and comparative risk, short- but not long-term
worries and expressed a stronger desire to quit. The lung
age of this cohort was over a decade older than physio-
logic age. It is unclear what magnitude of discrepancy
between measured and actual age can motivate behav-
ioral changes in this population. While lung age may be
beneficial in other populations, the lack of an observed
effect in IDUs highlights the need to study specific ces-
sation interventions in unique populations of smokers.
Several theoretical models of health behavior change,
including the health belief model, protection motivation
theory and precaution adoption models, propose that
perceptions of personal vulnerability to the harms of
smoking are key to motivating smoking cessation [58-60].
Additionally, greater perceived risk has been associated
with a greater desire to quit, more frequent quit attempts
and sustained quitting [61-64]. In addition to a lack of im-
pact of lung age as a motivational tool, the benefits of con-
tingency management were not seen when combined with
lung age intervention. Based on the null findings observed
with lung age-based risk counseling, the relationships be-
tween perceived risk and motivation for cessation may be
more complex among IDUs. Conceptual models of smok-
ing cessation include reinforcement-based motivational
therapy and augmentation of perceived personal risk.
Drummond et al. BMC Public Health 2014, 14:761 Page 8 of 10
http://www.biomedcentral.com/1471-2458/14/761Contingency management serves to motivate behavioral
change through reinforcement while lung age serves to
enhance perceived personal risk. Therefore, the lack of a
lung age effect in the population studied here suggests
that IDUs may be more responsive to incentives rather
than perceived self-risk. Further, the attenuation of contin-
gency management effects by the presence of lung age sug-
gest that lung age may serve as a negative reinforcement
of other cessation tools.
Unique strengths of this study include the focus on an
under-studied population with high tobacco dependence,
a study design permitting evaluation of the independent
and synergistic effects of two interventions, and the
near-complete 6-month follow-up. This study has some
limitations. The small sample size of this study limits the
ability to determine the efficacy or estimate the magni-
tude of the effect of contingency management or spiro-
metric lung age on smoking cessation. The data from
this study can be used to inform larger trials testing
these interventions. The durability of benefits from con-
tingency management after completion of the interven-
tion is not known, but will be evaluated with on-going
follow-up. While the overall rates of cessation were low,
a six month 7-11% biological cessation rate is likely
substantial in this challenging population of IDUs.
Intentionally, this study lacks generalizability outside of
urban, minority populations dealing with substance
abuse. Our goal was to examine specific cessation inter-
ventions among drug users, as this population has high
smoking prevalence, substantial tobacco-related disease
burden, extremely low cessation rates, and has been
greatly understudied in terms of cessation interventions.
This study demonstrates that tobacco cessation inter-
ventions can be effectively implemented in this popula-
tion. Novel cessation strategies, such as incorporating
mobile health (mHealth) tools to improve smoking ces-
sation among marginalized, underserved populations
holds promise for improving access and efficiency to
smoking cessation interventions and towards reducing
the tobacco-related disparities that currently exist [65].
Conclusions
In summary, we have demonstrated that contingency
management, but not spirometric lung age message, as a
motivational tool for smoking cessation leads to more
short-term abstinence and lower nicotine addiction over
a 6-month period. While definitive benefit on biologically-
confirmed smoking cessation at 6 months was not
achieved in this study, our findings demonstrate that con-
tingency management interventions are feasible among
urban drug-using populations and leads to favorable mod-
ifications in smoking behavior, specifically cessation at-
tempts and in reduced levels of nicotine addiction. Larger
trials among drug-using populations are appropriate todefinitively establish if contingency management is of
benefit in this population. Ultimately, contingency man-
agement may help decrease the substantial burden of to-
bacco dependence in similar underserved populations
with excessive tobacco use.
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